Grupo Financiero Galicia S.A. (NASDAQ:GGAL)
Grupo Financiero Galicia SA. is involved in the Financial Services Industry. Their principal activity is to continue to be a financial and investment services holding company and to fulfill the banking services activities of Banco Galicia.
Grupo Financiero Galicia S.A. (NASDAQ:GGAL)’s Financial Overview
Grupo Financiero Galicia S.A. (NASDAQ) surged 1.21% yesterday to close its trading session at $36.76. The company has 1 year Price Target of $29.12. Grupo Financiero Galicia S.A. has 52-Week high of $68.86 and 52-Week Low of $18.3. The stock touched its 52-Week High on 68.86 and 52-Week Low on 18.30. The stock traded with the volume of 915176 shares yesterday. The firm shows the market capitalization of $4.06 Billion.
Grupo Financiero Galicia S.A. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.93/share against the analyst consensus estimate of $0.72/share. The difference between the actual and expected EPS is $0.21 a share with a surprise factor of 29.2%.
The firm is trading with SMA20 of 6.6 Percent, SMA50 of 20.18 Percent and SMA200 of 12.19 percent. Grupo Financiero Galicia S.A. has P/S value of 2.87 while its P/B value stands at 3.93. Similarly, the company has Return on Assets of 3.2 percent, Return on Equity of 27.8 percent and Return on Investment of 21 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 34.4 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 3.1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 12 analysts offering 12-month price forecasts for Grupo Financiero Galicia SA have a median target of 28.50, with a high estimate of 43.38 and a low estimate of 24.00. The median estimate represents a -22.47% decrease from the last price of 36.76.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company’s electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio’s clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic) & avian influenza (preventative) & hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company’s partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)’s Financial Outlook
The 6 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 13.00 and a low estimate of 8.00. The median estimate represents a +134.54% increase from the last price of 4.69.
Inovio Pharmaceuticals, Inc. is estimated to report earnings on 03/13/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.3. The reported EPS for the same quarter last year was $-0.24.
According to Zacks Investment Research, Inovio Pharmaceuticals, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 1.3% and closed its last trading session at $4.69. The company has the market capitalization of $453.95 Million. The stock has 52-week high of $6.3 and 52-Week low of $3.64. The firm touched its 52-Week high on 6.30 and 52-Week low on 3.64. The company has volume of 645109 shares. The company has a total of 96.79 Million shares outstanding.
Inovio Pharmaceuticals, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.27/share where the analyst estimated EPS was $-0.3/share. The difference between the actual and Estimated EPS is $0.03. This shows a surprise factor of 10 percent.
The company has YTD performance of 17.25 percent. Beta for Inovio Pharmaceuticals, Inc. stands at 1.84 while its ATR (average true range) is 0.21. The company has Weekly Volatility of 3.64%% and Monthly Volatility of 4.48%%.
Inovio Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of -3.18%, Distance from 50-Day Simple Moving Average of -1.72 percent and Distance from 200-Day Simple Moving Average of -1.66%.
The Company currently has ROA (Return on Assets) of -52.6 percent, Return on Equity (ROE) of -72.7 Percent and Return on Investment (ROI) of -58.7% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.